Blood test identifies relapse risk; targeted drug shows promise

NCT ID NCT06680596

ENROLLING_BY_INVITATION Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study has two parts. First, it screens people with HR+ HER2-low metastatic breast cancer who are on standard CDK4/6 inhibitor therapy to find those with lingering tumor DNA in their blood—a sign of high relapse risk. Then, those high-risk patients receive the drug trastuzumab deruxtecan (T-DXd) to see if it can keep their cancer from getting worse. About 80 people will take part in this Phase 2 trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (T-DXd)
What this could lead to: If successful, this could offer a new treatment option for patients with HR+ HER2-low metastatic breast cancer who are at high risk of relapse despite standard therapy.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 80 participants, so results may not apply to all patients. The drug also has known side effects like lung inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER STAGE IV BREAST CANCER, METASTATIC

Contacts and locations

Locations

CHU de Nimes

Nîmes, 30029, France
Centre Antoine Lacassagne

Nice, 06189, France
Centre Eugene Marquis

Rennes, France
Centre Hospitalier Alpes Léman

Contamine-sur-Arve, 74130, France
Centre Hospitalier D'Auxerre

Auxerre, 89000, France
Centre Hospitalier William Morey

Chalon-sur-Saône, 71100, France
Centre Hospitalier de Beauvais

Beauvais, 60021, France
Centre Hospitalier de Boulogne-Sur-Mer

Boulogne-sur-Mer, 62321, France
Centre Hospitalier de Cholet

Cholet, 49300, France
Centre Hospitalier de Pau

Pau, 64046, France
Centre Hospitalier de la Côte Basque

Bayonne, 64100, France
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Léon Bérard

Lyon, 69008, France
Centre Médico-Chirurgical (Cmc) Ambroise Paré-Hartmann

Neuilly-sur-Seine, 92200, France
Chd Vendée

La Roche-sur-Yon, 85925, France
Chi Fréjus-Saint-Raphaël

Fréjus, 83608, France
Chp Saint-Grégoire - Groupe Vivalto Sante

Saint-Grégoire, 35760, France
Chu Amiens Picardie

Amiens, 80054, France
Chu de Brest - Hôpital Cavale Blanche

Brest, 29200, France
Clinique Pasteur Lanroze - Cfro - Groupe Vivalto Sante

Brest, 29200, France
Clinique Sainte-Anne - Gh Saint-Vincent

Strasbourg, 67000, France
Clinique de Flandre

Coudekerque-Branche, 59210, France
Clinique de L'Europe Amiens - Cthe

Amiens, 80090, France
Clinique de La Sauvegarde

Lyon, 69009, France
Groupe Hospitalier Diaconesses Croix Saint-Simon

Paris, 75020, France
Gustave Roussy

Villejuif, France
Hopital Prive Jean Mermoz

Lyon, 69008, France
Hopital Privé Des Côtes D'Armor (Hpca) - Cario

Plérin, 22190, France
Hôpital Saint-Louis

Paris, 75010, France
Hôpital Simone Veil de Blois

Blois, 41000, France
Hôpitaux Du Léman

Thonon-les-Bains, 74200, France
Icm Val D'Aurelle

Montpellier, 34298, France
Institut Godinot

Reims, 51100, France
Institut Paoli Calmettes

Marseille, 13009, France
Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, 054519, France
Medipôle de Nancy - Cog-Ilc (Polyclinique de Gentilly)

Nancy, 54100, France
Pôle Santé République (Elsan)

Clermont-Ferrand, 63000, France
Sainte Catherine Institut Du Cancer Avignon Provence

Avignon, 84918, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.